World IBS Day - April 19th: Educating Others about Irritable Bowel Syndrome
Are you the best you can be?
TORONTO, March 19, 2025 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder affecting 10-15% people globally with symptoms like abdominal pain, bloating, constipation, and diarrhea. Misunderstood and stigmatized, this condition significantly impacts individuals' quality of life. World IBS Day 2025 on April 19th, receives lead support from Ardelyx Inc. (United States).
The theme "Are you the best you can be" is aimed to educate patients and Healthcare Providers about the questions that IBS Patients have. Patients are asked to submit questions on the WorldIBSDay.org website. A free patient webinar with featured questions from patients, will be held on April 15 at 7pm EST. Additional 2025 events are listed on the World IBS Day website.
World IBS Day is now recognized in 17 countries and receives support from friends across the globe including our Partner Salix Pharmaceuticals (United States) and other partners Monash University ? FODMAP (Australia) and ModifyHealth (United States). Organizations, institutions, vendors, and industry are encouraged to add their events and support. World IBS Day events and social banners are available to download on the website. Use the hashtag #WorldIBSDay2025 to raise awareness on April 19th.
World IBS Day was established by Jeffrey Roberts, founder of the IBS Patient Support Group. His vision was to reduce stigma and support patients and caregivers, emphasizing evidence-based medicine and non-anecdotal treatment options for patients. Jeffrey has been an IBS sufferer for over 40 years, working closely with researchers, industry, and patients for over 30 years.
About Jeffrey Roberts:
Jeffrey Roberts, MSEd, BSc is an IBS Patient Advocate. He was the creator of the first internet community for IBS sufferers in 1995. He currently runs IBSpatient.org, is the co-founder of TuesdayNightIBS.com and founded World IBS Day in 2019. He has testified to the US FDA numerous sharing what is like to live with IBS. He was the recent recipient of a Social Media Acumen Award from the American College of Gastroenterology (ACG).
About Ardelyx, Inc.:
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada., please visit ardelyx.com.
Media Contact:
Jeffrey Roberts
203-424-0660
392143@email4pr.com
SOURCE World IBS Day
These press releases may also interest you
|
News published on and distributed by:
